Skip to content

Public FDA record

Z-2295-2020: FilmArray BCID Panel, RFIT-ASY-0126, 30, Rx Only, CE, IVD, UDI: 00815381020086 used with the following

Recall record Z-2295-2020 for BioFire Diagnostics, LLC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2295-2020
Company in FDA record
BioFire Diagnostics, LLC
FDA record creation date
Jun 8, 2020
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

There is an increased risk of false positive Proteus results when using the Film Array Blood Culture Identification Panel (BCID) in vitro diagnostic test of blood cultures used in conjunction with specific media types. False positive Proteus results from this test may lead to patients receiving improper antibiotic treatment until culture results are available (within 24-48 hours).

Source facts

Action
The firm's recall strategy is notification of all customers that have ordered the FilmArray BCID Panel using Urgent: Medical Device Correction, FSCA 4593 Letters. The letters to US customers were sent via FedEx to The US letters were mailed on January 22, 2020, via FedEx Overnight, with delivery on January 23, 2020 to the Recall Coordinator/MicroLab Director for all organizations that have ordered FilmArray BCID kits.. The OUS customer communication was issued by bioMrieux (parent company) on January 24, 2020. The letter informed customers that BioFire Diagnostics, LLC has identified an increased risk of false positive Proteus results (appearing as Enterobacteriaceae/Proteus on the test report) when the BioFire BCID Panel is used with some BACT/ALERT blood culture bottles (see Table 1) with expiration dates of 19SEP2020 and beyond. It lists the following actions to be taken by the customer: the BioFire BCID Panel is used to test BACT/ALERT blood culture bottles (Table 1) with an expiration date of 19SEP2020 and beyond, positive results for Proteus should be confirmed by another method prior to reporting the test results. This letter supersedes all previous communications regarding Proteus false positive results using bioMrieux blood culture bottles. Please complete the accompanying Field Action Acknowledgment of Receipt Form and return to BioFire via one of the listed return methods so that BioFire may acknowledge your receipt of this notification. If customers have any questions or concerns, they should contact the customer service department at Support@biofiredx.com or via telephone by dialing 1.800.735.6544 and selecting option 5 for product technical support. Adverse events may also be reported to FDAs MedWatch Adverse Event Reporting program.
Initiated
2020-01-22
Root cause
Under Investigation by firm
Terminated
2021-04-14
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Argentina, Austria, Australia, Azerbaijan, Belgium, Bosnia-Herz., Botswana, Brazil, Bulgaria, Burkina Faso, Canada, Chile, Columbia, Costa Rica, Croatia, Czech Republic, Dominican Republic, Dutch Antilles, Ecuador, Egypt, El Salvador, Estonia, France, Gabon, Georgia, Germany, Greece, Guam, Guatemala, Honduras, Hong Kong, Hungary, India, Indonesia, Iraq, Israel, Italy, Ivory Coast, Japan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Mexico, Morocco, Myanmar, Netherlands, Nicaragua, Oman, Pakistan, Panama, Paraguay, Peru, Phillipines, Poland, Portugal, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, South Korea, Spain, Sweden, Sitzerland, Thailand, Tunisia, Turkey, United Kingdom, Uruguay, United Arab Emirates, Vietnam.
Recall number
Z-2295-2020
Recall status
Terminated
CDRH record ID
181222
FDA record created
2020-06-08
Recall event number
85550

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗